Akari Therapeutics (AKTX) Competitors $0.97 -0.03 (-2.99%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends AKTX vs. TNXP, MIST, COYA, EPRX, NVCT, RANI, ADAG, ANIX, ASRT, and MEShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Tonix Pharmaceuticals (TNXP), Milestone Pharmaceuticals (MIST), Coya Therapeutics (COYA), Eupraxia Pharmaceuticals (EPRX), Nuvectis Pharma (NVCT), Rani Therapeutics (RANI), Adagene (ADAG), Anixa Biosciences (ANIX), Assertio (ASRT), and 23andMe (ME). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Tonix Pharmaceuticals Milestone Pharmaceuticals Coya Therapeutics Eupraxia Pharmaceuticals Nuvectis Pharma Rani Therapeutics Adagene Anixa Biosciences Assertio 23andMe Akari Therapeutics (NASDAQ:AKTX) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk. Do insiders & institutionals believe in AKTX or TNXP? 5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 38.9% of Akari Therapeutics shares are held by insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media prefer AKTX or TNXP? In the previous week, Tonix Pharmaceuticals had 11 more articles in the media than Akari Therapeutics. MarketBeat recorded 14 mentions for Tonix Pharmaceuticals and 3 mentions for Akari Therapeutics. Tonix Pharmaceuticals' average media sentiment score of 0.33 beat Akari Therapeutics' score of 0.25 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tonix Pharmaceuticals 1 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in AKTX or TNXP? Tonix Pharmaceuticals received 78 more outperform votes than Akari Therapeutics when rated by MarketBeat users. Likewise, 61.48% of users gave Tonix Pharmaceuticals an outperform vote while only 51.68% of users gave Akari Therapeutics an outperform vote. CompanyUnderperformOutperformAkari TherapeuticsOutperform Votes26251.68% Underperform Votes24548.32% Tonix PharmaceuticalsOutperform Votes34061.48% Underperform Votes21338.52% Which has more risk and volatility, AKTX or TNXP? Akari Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.23, suggesting that its stock price is 123% more volatile than the S&P 500. Do analysts recommend AKTX or TNXP? Tonix Pharmaceuticals has a consensus price target of $53.50, indicating a potential upside of 8,647.55%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, AKTX or TNXP? Akari Therapeutics has higher earnings, but lower revenue than Tonix Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$10.01MN/AN/ATonix Pharmaceuticals$11.29M10.12-$116.66M-$52.74-0.01 Is AKTX or TNXP more profitable? Akari Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. Akari Therapeutics' return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A N/A N/A Tonix Pharmaceuticals -1,197.86%-163.95%-118.88% SummaryTonix Pharmaceuticals beats Akari Therapeutics on 10 of the 15 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.68M$6.57B$5.13B$9.08BDividend YieldN/A2.99%4.93%4.22%P/E RatioN/A10.5589.5817.18Price / SalesN/A195.351,115.01116.87Price / CashN/A57.1642.8237.86Price / Book-32.335.104.804.78Net Income-$10.01M$151.51M$120.04M$225.60M7 Day Performance-0.31%-2.12%-1.91%-1.23%1 Month Performance-21.77%-3.10%11.48%3.36%1 Year Performance-68.20%11.54%30.59%16.59% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari TherapeuticsN/A$0.97-3.0%N/A-67.2%$25.68MN/A0.009Analyst ForecastGap DownTNXPTonix Pharmaceuticals3.6175 of 5 stars$0.51+113.1%$53.50+10,337.0%-95.0%$95.80M$11.29M0.00103High Trading VolumeMISTMilestone Pharmaceuticals1.6334 of 5 stars$1.80-0.3%$12.00+568.5%-34.8%$95.72M$1M-2.2230Positive NewsCOYACoya Therapeutics2.1484 of 5 stars$5.69-3.4%$16.25+185.6%-23.7%$95.06M$9.55M-9.066Analyst ForecastPositive NewsGap DownEPRXEupraxia Pharmaceuticals2.2152 of 5 stars$3.48+1.2%$9.00+158.6%N/A$94.94MN/A-4.7829Gap DownNVCTNuvectis Pharma3.2417 of 5 stars$4.86+3.4%$21.00+332.1%-45.3%$93.90MN/A-4.058Positive NewsRANIRani Therapeutics3.4527 of 5 stars$1.63-1.8%$11.71+618.7%-55.1%$93.38M$2.72M-1.57110Positive NewsADAGAdagene1.9972 of 5 stars$2.05-0.5%$5.00+143.9%+13.9%$90.76M$815,746.000.00260ANIXAnixa Biosciences2.9529 of 5 stars$2.81-1.4%$8.50+202.5%-28.8%$90.42M$210,000.00-7.315Positive NewsASRTAssertio3.3686 of 5 stars$0.94+2.7%$3.25+244.1%-14.8%$90.17M$125.76M-1.2620Gap DownME23andMe2.3629 of 5 stars$3.45+3.0%$9.40+172.5%-81.5%$90.11M$219.64M-0.13770Positive News Related Companies and Tools Related Companies Tonix Pharmaceuticals Competitors Milestone Pharmaceuticals Competitors Coya Therapeutics Competitors Eupraxia Pharmaceuticals Competitors Nuvectis Pharma Competitors Rani Therapeutics Competitors Adagene Competitors Anixa Biosciences Competitors Assertio Competitors 23andMe Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AKTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKTX Stock Alerts